Hoffman Alexander F, Oz Murat, Yang Ruiqin, Lichtman Aron H, Lupica Carl R
United States Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Intramural Research Program, Cellular Neurobiology Branch, Electrophysiology Research Unit, Baltimore, Maryland 21224, USA.
Learn Mem. 2007 Jan 3;14(1-2):63-74. doi: 10.1101/lm.439007. Print 2007 Jan-Feb.
Memory deficits produced by marijuana arise partly via interaction of the psychoactive component, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), with cannabinoid receptors in the hippocampus. Although cannabinoids acutely reduce glutamate release and block hippocampal long-term potentiation (LTP), a potential substrate for learning and memory, the consequences of prolonged exposure to Delta(9)-THC for hippocampal function are poorly understood. Rats were injected with Delta(9)-THC (10 mg/kg, i.p., q.d.) for 1, 3, or 7 d, and electrophysiological recordings were performed in hippocampal slices 1d after the final injection. At this time, Delta(9)-THC was undetectable in hippocampus using liquid chromatography-mass spectrometry (LC-MS). Hippocampal LTP generated using high-frequency (HFS) or theta burst stimulation was not observed in brain slices from the 7-d Delta(9)-THC-treated animals. Delta(9)-THC also blocked HFS-LTP after 3 d, but not 1 d of treatment. The complete blockade of LTP persisted for 3 d after the last Delta(9)-THC injection, and full reversal of the LTP deficit was not observed up to 14 d following Delta(9)-THC withdrawal. The cannabinoid antagonist AM251 (2 mg/kg), administered before each Delta(9)-THC injection prevented the blockade of LTP, and 7-d treatment with AM251 alone significantly increased the level of LTP. Chronic Delta(9)-THC also produced tolerance to the inhibition of synaptic GABA, but not glutamate release by the agonist WIN55,212-2. These data define consequences of repeated Delta(9)-THC exposure for synaptic plasticity in the hippocampus that may help explain memory impairments in humans following chronic marijuana use.
大麻导致的记忆缺陷部分是通过其精神活性成分Δ⁹-四氢大麻酚(Δ⁹-THC)与海马体中的大麻素受体相互作用产生的。尽管大麻素会急性减少谷氨酸释放并阻断海马体长期增强(LTP),而LTP是学习和记忆的潜在底物,但长期暴露于Δ⁹-THC对海马体功能的影响却知之甚少。给大鼠腹腔注射Δ⁹-THC(10毫克/千克,每日一次),持续1、3或7天,在最后一次注射后1天对海马体切片进行电生理记录。此时,使用液相色谱-质谱联用(LC-MS)在海马体中未检测到Δ⁹-THC。在接受7天Δ⁹-THC处理的动物的脑切片中,未观察到使用高频(HFS)或theta爆发刺激产生的海马体LTP。Δ⁹-THC处理3天后也会阻断HFS-LTP,但处理1天后不会。最后一次注射Δ⁹-THC后,LTP的完全阻断持续了3天,在Δ⁹-THC撤药后长达14天未观察到LTP缺陷的完全逆转。在每次注射Δ⁹-THC之前给予大麻素拮抗剂AM251(2毫克/千克)可防止LTP的阻断,单独用AM251进行7天治疗可显著提高LTP水平。慢性给予Δ⁹-THC还会使对激动剂WIN55,212-2抑制突触GABA释放产生耐受性,但对谷氨酸释放则不会。这些数据确定了重复暴露于Δ⁹-THC对海马体突触可塑性的影响,这可能有助于解释长期使用大麻后人类的记忆障碍。